Jump to content

Justin Stebbing

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 79OLIVER19 (talk | contribs) at 15:29, 20 August 2023. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

PROFESSOR JUSTIN STEBBING BLACK AND WHITE


Justin Stebbing is editor-in-chief of Nature’s cancer journal Oncogene,[1] a visiting Professor of Cancer Medicine and Oncology at Imperial College, London [2] and a Professor of Biomedical Sciences at ARU, Cambridge.[3] In October 2022 he joined the Phoenix Hospital Group in London to provide medical services to patients for the management of cancer, in person and remotely.[4] He specialises in a range of solid malignancies (breast, GI, lung, others) including difficult cases with few conventional options and has published over 700 papers, the majority regarding new therapeutic and translational approaches including use of immunotherapies in clinical trials, many in the world's best journals.

Early life and education

He graduated with a first class degree from Trinity College, Oxford. After completion of junior doctor positions in Oxford, he trained as on the residency programme at The Johns Hopkins Hospital in the US, returning to London to continue his career in oncology at The Royal Marsden and then St Bartholomew's Hospitals. Stebbing's original PhD research investigated the interplay between the immune system and cancer. In 2007 he was appointed a senior lecturer, and then in 2009 a professor, at Imperial College London.[5]

Cancer research

He has published over 700 peer-reviewed papers in academic journals [6] [7] and has an h-index of 87 according to Google Scholar[8] [6] He is an Editor-in-Chief of the journal Oncogene.[9] He is a Fellow of the Royal College of Physicians,[citation needed] the American Society for Clinical Investigation[10] and the Royal College of Pathologists.[citation needed] The charity Action Against Cancer was set up to support Justin's work which concentrates on drug development and has the ambitious goal of developing cures.[11] In cancer, some of his most cited papers include the discovery of the role of the oncogene LMTK3 across malignancies, the network of microRNAs induced by the estrogen receptor, and extensive work on HIV and AIDS cancers.[12][13][14][15] In addition to his global contributions to cancer research including extensive work on biosimilars, cheaper versions of expensive biologic drugs designed to democratise access to these around the world in 2020 at the start of the pandemic.[16]

COVID-19 research

In addition to his global contributions to cancer research including new discoveries on stem cells, new cancer genes, biomarkers and also biosimilar studies.[5] Professor Justin Stebbing made a global contribution to millions of lives by leveraging an artificial intelligence programme to identify baricitinib as a drug for the treatment of COVID-19 in early 2020.[17] Uniquely this had antiviral and anti-cytokine properties. He led the global studies that showed that the drug reduced mortality in Covid patients with pneumonia — which led to the drug being authorised by the US Food and Drug Administration in 2020 at first in combination with remdesivir, then alone.[18] His original Lancet papers have been cited >1000 times, and recent editorials in the New England Journal of Medicine and Lancet Respiratory Medicine describe this further, along with the major studies he led .[19] The book, ‘Witness to COVID, 2020’ [20] was written by Justin Stebbing describing its discovery, trials,[21] studies and approval.[22] In January 2022, following Professor Stebbing's pivotal original papers and the subsequent global trials, the World Health Organization placed baricitinib at the top of its evidence base to treat COVID, giving it its highest recommendation.[23][24][25] This has also been made free to countries around the world as they have struggled with numbers of patients, considering it is a simple once daily tablet with few drug-drug interactions, side effects, has dose flexibility, a short half-life and is cheap as his work here has outlined.[26][27][28] Based on Prof Stebbing's original AI hypothesis, following the success of the clinical trials including RECOVERY, in May 2022 the US FDA gave baricitinib an unconditional approval. [29] [30] [31]

Neurological research

Professor Stebbing works actively on neurological therapies for patients with unmet medical needs who are treatment resistant or unresponsive to other existing medications. [32]

MPTS

In 2020, Professor Justin Stebbing was investigated by the General Medical Council over allegations that he failed to provide adequate care to eleven patients with no further options who he had cared for between 2014 and 2017 and he returned to unrestricted practice in October 2022 [33]

References

  1. ^ "About the Editors | Oncogene". www.nature.com. Retrieved 2022-10-29.
  2. ^ "Home - Professor Justin Stebbing". www.imperial.ac.uk. Retrieved 2022-10-29.
  3. ^ "Professor Justin Stebbing - ARU". aru.ac.uk. Retrieved 2022-11-30.
  4. ^ "Professor Justin Stebbing". Phoenix Hospital Group. Retrieved 2022-10-29.
  5. ^ a b "PWP Messages".
  6. ^ a b "Justin Stebbing". scholar.google.com. Retrieved 2022-05-25.
  7. ^ Home - Professor Justin Stebbing (imperial.ac.uk)
  8. ^ "Justin Stebbing". scholar.google.com. Retrieved 28 March 2023.
  9. ^ "About the Editors". Oncogene.
  10. ^ "The American Society for Clinical Investigation".
  11. ^ "Home | Action Against Cancer". www.aacancer.org. Retrieved 28 March 2023.
  12. ^ Giamas, Georgios; Filipović, Aleksandra; Jacob, Jimmy; Messier, Walter; Zhang, Hua; Yang, Dongyun; Zhang, Wu; Shifa, Belul Assefa; Photiou, Andrew; Tralau-Stewart, Cathy; Castellano, Leandro; Green, Andrew R.; Coombes, R. Charles; Ellis, Ian O.; Ali, Simak; Lenz, Heinz-Josef; Stebbing, Justin (June 2011). "Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer". Nature Medicine. 17 (6): 715–719. doi:10.1038/nm.2351. PMID 21602804. S2CID 5279914.[non-primary source needed]
  13. ^ Castellano, Leandro; Giamas, Georgios; Jacob, Jimmy; Coombes, R. Charles; Lucchesi, Walter; Thiruchelvam, Paul; Barton, Geraint; Jiao, Long R.; Wait, Robin; Waxman, Jonathan; Hannon, Gregory J.; Stebbing, Justin (21 August 2009). "The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response". Proceedings of the National Academy of Sciences. 106 (37): 15732–15737. Bibcode:2009PNAS..10615732C. doi:10.1073/pnas.0906947106. PMC 2747188. PMID 19706389.[non-primary source needed]
  14. ^ Bower, M.; Nelson, M.; Young, A.M.; Thirlwell, C.; Newsom-Davis, T.; Mandalia, S.; Dhillon, T.; Holmes, P.; Gazzard, B.G.; Stebbing, J. (1 August 2005). "Immune Reconstitution Inflammatory Syndrome Associated With Kaposi's Sarcoma". Journal of Clinical Oncology. 23 (22): 5224–5228. doi:10.1200/JCO.2005.14.597. PMID 16051964.[non-primary source needed]
  15. ^ Stebbing, Justin; Gazzard, Brian; Douek, Daniel C. (29 April 2004). "Where Does HIV Live?". New England Journal of Medicine. 350 (18): 1872–1880. doi:10.1056/NEJMra032395. PMID 15115833.[non-primary source needed]
  16. ^ Stebbing, Justin; Baranau, Yauheni; Baryash, Valeriy; Manikhas, Alexey; Moiseyenko, Vladimir; Dzagnidze, Giorgi; Zhavrid, Edvard; Boliukh, Dmytro; Stroyakovskii, Daniil; Pikiel, Joanna; Eniu, Alexandru; Komov, Dmitry; Morar-Bolba, Gabriela; Li, Rubi K.; Rusyn, Andriy; Lee, Sang Joon; Lee, Sung Young; Esteva, Francisco J. (1 July 2017). "CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial". The Lancet Oncology. 18 (7): 917–928. doi:10.1016/S1470-2045(17)30434-5. hdl:10044/1/52810. PMID 28592386.[non-primary source needed]
  17. ^ Richardson, Peter; Griffin, Ivan; Tucker, Catherine; Smith, Dan; Oechsle, Olly; Phelan, Anne; Rawling, Michael; Savory, Edward; Stebbing, Justin (15 February 2020). "Baricitinib as potential treatment for 2019-nCoV acute respiratory disease". The Lancet. 395 (10223): e30–e31. doi:10.1016/S0140-6736(20)30304-4. PMC 7137985. PMID 32032529.[non-primary source needed]
  18. ^ "Potential treatment for COVID-19 identified by BenevolentAI enters randomised clinical trial | BenevolentAI". www.benevolent.com. Retrieved 2022-01-11.
  19. ^ "FDA authorizes baricitinib alone as treatment for COVID-19".
  20. ^ Stebbing, Justin (15 November 2021). Witness to Covid: 2020 | Justin Stebbing | London Review Bookshop. ISBN 9781398112674.
  21. ^ Kalil, Andre C; Stebbing, Justin (December 2021). "Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial". The Lancet Respiratory Medicine. 9 (12): 1349–1351. doi:10.1016/S2213-2600(21)00358-1. PMC 8409093. PMID 34480862.[non-primary source needed]
  22. ^ Stebbing, Justin; Lauschke, Volker M. (29 July 2021). "JAK Inhibitors — More Than Just Glucocorticoids". New England Journal of Medicine. 385 (5): 463–465. doi:10.1056/NEJMe2108667. PMC 8362590. PMID 34320294.[non-primary source needed]
  23. ^ Kmietowicz, Zosia (14 January 2022). "Covid-19: WHO recommends baricitinib and sotrovimab to treat patients". BMJ. 376: o97. doi:10.1136/bmj.o97. PMID 35027362. S2CID 245907930.
  24. ^ Agarwal, Arnav; Rochwerg, Bram; Lamontagne, François; Siemieniuk, Reed AC; Agoritsas, Thomas; Askie, Lisa; Lytvyn, Lyubov; Leo, Yee-Sin; Macdonald, Helen; Zeng, Linan; Amin, Wagdy; Barragan, Fabian AJ; Bausch, Frederique J.; Burhan, Erlina; Calfee, Carolyn S.; Cecconi, Maurizio; Chanda, Duncan; Dat, Vu Quoc; Sutter, An De; Du, Bin; Geduld, Heike; Gee, Patrick; Harley, Nerina; Hashmi, Madiha; Hunt, Beverley; Jehan, Fyezah; Kabra, Sushil K.; Kanda, Seema; Kim, Yae-Jean; Kissoon, Niranjan; Krishna, Sanjeev; Kuppalli, Krutika; Kwizera, Arthur; Lisboa, Thiago; Mahaka, Imelda; Manai, Hela; Mino, Greta; Nsutebu, Emmanuel; Preller, Jacobus; Pshenichnaya, Natalia; Qadir, Nida; Sabzwari, Saniya; Sarin, Rohit; Shankar-Hari, Manu; Sharland, Michael; Shen, Yinzhong; Ranganathan, Shalini S.; Souza, Joao P.; Stegemann, Miriam; Swanstrom, Ronald; Ugarte, Sebastian; Venkatapuram, Sridhar; Vuyiseka, Dubula; Wijewickrama, Ananda; Maguire, Brittany; Zeraatkar, Dena; Bartoszko, Jessica J.; Ge, Long; Brignardello-Petersen, Romina; Owen, Andrew; Guyatt, Gordon; Diaz, Janet; Kawano-Dourado, Leticia; Jacobs, Michael; Vandvik, Per Olav (4 September 2020). "A living WHO guideline on drugs for covid-19". BMJ. 370: m3379. doi:10.1136/bmj.m3379. PMID 32887691. S2CID 221498813.
  25. ^ "WHO recommends Eli Lilly, GSK-Vir's drugs, widening COVID-19 treatment pool". Reuters. 13 January 2022.
  26. ^ https://www.benevolent.com/news/who-recommends-baricitnib-for-hospitalised-patients-with-covid-19
  27. ^ "Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements" (Press release). Eli Lilly. 4 May 2021.
  28. ^ Stebbing, Justin; Krishnan, Venkatesh; Bono, Stephanie; Ottaviani, Silvia; Casalini, Giacomo; Richardson, Peter J; Monteil, Vanessa; Lauschke, Volker M; Mirazimi, Ali; Youhanna, Sonia; Tan, Yee‐Joo; Baldanti, Fausto; Sarasini, Antonella; Terres, Jorge A Ross; Nickoloff, Brian J; Higgs, Richard E; Rocha, Guilherme; Byers, Nicole L; Schlichting, Douglas E; Nirula, Ajay; Cardoso, Anabela; Corbellino, Mario (7 August 2020). "Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID ‐19 patients". EMBO Molecular Medicine. 12 (8): e12697. doi:10.15252/emmm.202012697. PMC 7300657. PMID 32473600.[non-primary source needed]
  29. ^ Stebbing, Justin; Phelan, Anne; Griffin, Ivan; Tucker, Catherine; Oechsle, Olly; Smith, Dan; Richardson, Peter (2020-04-01). "COVID-19: combining antiviral and anti-inflammatory treatments". The Lancet Infectious Diseases. 20 (4): 400–402. doi:10.1016/S1473-3099(20)30132-8. ISSN 1473-3099. PMC 7158903. PMID 32113509.
  30. ^ "New RECOVERY trial result: baricitinib reduces deaths in patients hospitalised with COVID-19 — RECOVERY Trial". www.recoverytrial.net. Retrieved 2022-05-13.
  31. ^ "FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 | Eli Lilly and Company". investor.lilly.com. Retrieved 2022-05-13.
  32. ^ "Home". Équilibre Biopharmaceuticals Corp. Retrieved 2022-05-25.
  33. ^ "Professor Justin STEBBING Oct 22 - MPTS". Retrieved 28 March 2023.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Justin_Stebbing&oldid=1171345215"